# AGEN catalysts: AGENUS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/agen/catalysts

> AGENUS INC (AGEN) has 2 upcoming catalysts. The next is the Botvymo® (botensilimab) primary completion, September 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AGENUS INC |
| Ticker | AGEN (Nasdaq) |
| SEC CIK | 1098972 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/agen |

## Cash runway

Cash $86.9M as of 2026-09-30; quarterly burn $20.1M; about 13.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-449984).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2021 | [AGEN1777 trial start](https://sec-api.dev/pdufa/agen1777) | AGEN |  | completed | "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1098972/000095017024125608/agen-20240930.htm)) |
| Dec 2023 | [AGEN1777 trial start](https://sec-api.dev/pdufa/agen1777) | AGEN |  | completed | "In October 2021, we achieved a $20.0 million milestone upon the dosing of the first patient in the AGEN1777 Phase 1 clinical trial and in December 2023, we announced that the first patient was dosed in an AGEN1777 Phase 2 clinical trial, triggering the achievement of a $25.0 million milestone." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1098972/000119312526108632/agen-20251231.htm)) |
| November 12, 2024 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017024124543/agen-ex99_1.htm)) |
| March 11, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025036829/agen-ex99_1.htm)) |
| May 12, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Q1 2025 Financial Results and Key Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/agen-ex99_1.htm)) |
| August 11, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/agen-ex99_1.htm)) |
| November 10, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "LEXINGTON, Mass. — November 10, 2025 — Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/agen-ex99_1.htm)) |
| January 5, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Pancreatic Ductal Adenocarcinoma | completed | "NCT05630183 (A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-05 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05630183)) |
| March 16, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "LEXINGTON, Mass. — March 16, 2026 — Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program across patient access, clinical execution, and commercial readiness." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/agen-ex99_1.htm)) |
| April 27, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Advanced Melanoma | withdrawn | "NCT05529316 (A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05529316)) |
| May 11, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526215838/agen-ex99_1.htm)) |
| August 6, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-ex99_1.htm)) |
| November 5, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526448637/agen-ex99_1.htm)) |
| September 2027 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Colorectal Cancer | scheduled | "NCT05608044 (A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608044)) |
| Sep to Dec 2027 | [Botvymo® (botensilimab) topline data readout](https://sec-api.dev/pdufa/botensilimab) | AGEN | Metastatic Colorectal Cancer | scheduled | "NCT05608044 (A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05608044)) |

## Drugs

- [AGEN1777](https://sec-api.dev/pdufa/agen1777): 
- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab): Advanced Melanoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/agen/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AGEN catalysts: AGENUS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/agen/catalysts

```bibtex
@misc{secapidev_companies_agen_catalysts_20261116,
  title        = {AGEN catalysts: AGENUS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/agen/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_agen_catalysts_20261116","title":"AGEN catalysts: AGENUS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/agen/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
